Dexamethasone palmitate successfully attenuates hemophagocytic syndrome after allogeneic stem cell transplantation: macrophage-targeted steroid therapy.
|
| Abstract |
Hemophagocytic syndrome (HPS) induced by uncontrolled macrophage activation and subsequent graft failure is a frequent and prominent complication after allogeneic stem cell transplantation (allo-SCT), a cause of severe morbidity and death, and a therapeutic challenge. Liposome-incorporated dexamethasone, dexamethasone palmitate (DP), shows greater efficacy against macrophages as compared to dexamethasone sodium phosphate (DSP). Based on our findings that DP achieves significantly larger decrease than DSP on the viability of primary human macrophages compared in vitro, we tested the effects of DP in patients with HPS. A decrease in number of macrophages in the bone marrow and prevention of engraftment failure were observed in all patients without any severe complications. In conclusion, these data provide a rationale for testing DP as a first-line treatment for patients with HPS after allo-SCT.
|
|---|---|
| Authors | Satoshi Nishiwaki, Takayuki Nakayama, Makoto Murata, Tetsuya Nishida, Kyoko Sugimoto, Shigeki Saito, Tomonori Kato, Hiroki Mizuno, Nobuhiko Imahashi, Aika Seto, Yukiyasu Ozawa, Tatsunori Goto, Daisuke Koyama, Emi Yokohata, Naomi Kubota, Sonoko Kamoshita, Koichi Miyamura, Kimikazu Matsumoto, Masafumi Ito, Tomoki Naoe |
| Journal | International journal of hematology (Int J Hematol) Vol. 95 Issue 4 Pg. 428-33 (Apr 2012) ISSN: 1865-3774 [Electronic] Japan |
| PMID | 22351164 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't) |
| Chemical References |
|
| Topics |
|
Join CureHunter, for free Research Interface BASIC access!
Realize the full power of the drug-disease research graph!